Business · Companies · 1 hr ago
Celltrion wins Brazil government tender for Herzuma for seventh straight year
Celltrion won Brazil’s federal tender for Herzuma, its medicine for breast and stomach cancers.
The win marks the seventh straight year the company has secured the government contract, which it first won in 2020.
Celltrion’s Brazilian subsidiary will supply about 1 million vials exclusively through the end of next year.
Herzuma has about half of the Brazilian market and ranks first in prescriptions, the company said.
Brazil’s medicine market is divided between public procurement run by the federal government and private purchasing by hospitals, with the public market making up about 80% of the total.
The contract strengthens Celltrion’s position in Brazil’s public market.
The company plans to expand prescriptions and launch other medicines in Brazil, with two launches targeted by year-end.
Celltrion won Brazil’s federal government tender for Herzuma, extending its winning record to seven consecutive years.
The company said the tender wins began in 2020 and continued through 2026.
Celltrion’s Brazilian subsidiary will be the sole supplier of about 1 million vials of Herzuma through the end of 2027.
Herzuma, a trastuzumab treatment for breast and stomach cancer, has about 50% of the Brazilian market and leads prescriptions, according to Celltrion.
Celltrion plans to expand sales of existing products and launch new products in Brazil.
- Who
- Celltrion and its Brazilian subsidiary.
- What
- Celltrion won Brazil’s federal government tender for Herzuma for the seventh consecutive year. Its Brazilian subsidiary will supply about 1 million vials.
- When
- Celltrion announced the win on November 17, 2026. The supply is planned through the end of 2027.
- Where
- Brazil.
- Why
- Not stated
This story does not have two clearly opposing sides.
Herzuma first won a Brazilian government tender, according to Celltrion.
Celltrion announced it had won the tender for the seventh consecutive year.
Celltrion’s Brazilian subsidiary is to complete its planned supply of about 1 million vials.
- Tender record
- Seven consecutive years, from 2020 through 2026
- Planned supply
- About 1 million vials
- Supply period
- Through the end of 2027
- Brazil market share
- About 50%
- Drug
- Herzuma, whose active ingredient is trastuzumab